Exabis Library
Welcome to the e-CCO Library!
P677: Patients with Inflammatory Bowel Diseases on anti-TNF treatment have impaired antibody production after Anti-SARS-CoV-2 vaccination: Results from a Panhellenic registry
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P678 Effect of accelerated infliximab induction on short-term outcomes of paediatric acute severe ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P678: Definition of a microbial signature as a predictor of post-surgical recurrence in patients with Crohn's disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P678: Did toxicity profile of azathioprine changed within the last 10 years: comparative 17 years data from a single tertiary IBD center
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P678: Rare and severe complications in paediatric Inflammatory Bowel Disease: results of 5 years of international collaboration through the PIBD-SETQuality Safety Registry
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P678: Risk of malnutrition in patients with inflammatory bowel diseases: Results from an Italian multi-centre observational cross-sectional study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P678: Treatment of moderate to severe UC patients with new 5ASA tablets
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P678: Ustekinumab therapy improves the nutritional status in patients with Crohn's Disease. A prospective study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P679 What is the best strategy after failure to anti-TNF? Ustekinumab or other anti-TNF?
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P679: Development of a novel auto-injector of subcutaneous CT-P13 infliximab: Phase I randomised, open-label, single-dose trial to compare the pharmacokinetics and safety to pre-filled syringe in healthy subjects
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P679: Inflammatory Bowel Disease and cancer risk in the IBSEN study after 30 years of follow-up.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P679: Infliximab biosimilar CT-P13 in inflammatory bowel disease patients that require intensification treatment
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P679: Is the burden of obesity in IBD bigger than just weight?
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P679: Risk factors for disease relapse after stepping down from combination to anti-TNF monotherapy in children with IBD
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P679: The keystone bacterium Christensenella minuta improves colitis in in vivo preclinical Inflammatory Bowel Disease models
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P680 Biological treatment and potential risk of adverse postoperative outcome in patients with inflammatory bowel disease: An open-source expert panel review of the current literature and perspectives
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P680: A real-life experience of Crohn's Disease Exclusion Diet use at disease onset and as an add-on therapy in pediatric Crohn's disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P680: Epidemiology of Inflammatory Bowel Disease in Poland 2009-2020: nationwide data
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P680: Long-term efficacy of ustekinumab with and without concomitant immunosuppressants for Crohn’s disease: results from IM-UNITI long-term extension through 2 years
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P680: Machine learning (ML) in RCU-operated patients: Can we predict postoperative complications?
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM